Annual Report Overview 2023

By 2030, our KYSO® (knock-your-socks-off) antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.


Read our 2023 Annual Report

Read our 2023 Corporate Responsibility Report

Investor Conference Call on FY results/Annual Report 2023

Listen to Webcast

ANNUAL REPORT 2023

Financial Highlights

Market Cap, DKKb

142

(2023 year-end market cap)

Revenue, DKKm

16,474

(2023)

2023 Operating Expenses, DKKm

10,927

(70% invested in R&D)

Genmab

SHAREHOLDER LETTER

“2023 was a standout year for Genmab. For many years our team was a small one, but it was dedicated — dedicated to the idea that Genmab’s innovations could someday make a difference in the lives of people with cancer. That someday is today.”

Jan G. J. van de Winkel, Ph.D. President & CEO


Financial Review

“In 2023, we delivered on our priorities: successfully launching in the U.S. and Japan, advancing our mid/late stage pipeline, and scaling our discovery engine, accelerating our path towards our long-term strategic goals.”

Anthony Pagano, Executive Vice President & Chief Financial Officer

Corporate Governance Report 2023

View Report


Compensation Report 2023

View Report

GENMAB IN SHORT

Genmab is a leading international biotechnology company that creates, develops and commercializes antibody products to transform the treatment of cancer

  • 8

    Approved therapies incorporating Genmab innovation

  • 4

    Proprietary Genmab technologies

  • ~20

    Products in clinical development incorporating Genmab innovation

Corporate Social Responsibility

We are committed to being a sustainable, socially responsible biotech company. This commitment is anchored in our vision, core purpose and values, focused for impact through our CSR strategy, and lived every day by our team. It is fundamental to the way we do business.



Read our 2023 Corporate Responsibility Report

Get in touch

Contact our media relations team for press inquiries. If you have a general inquiry, please contact the Genmab switchboard at +45 7020 2728. We will handle your personal data in accordance with our Privacy Policy.

  • Marisol Peron

    Senior Vice President,
    Communications and Corporate Affairs

    Telephone: +1 609 524 0065

    777 Scudders Mill Road
    Plainsboro, NJ 08536
    USA

  • Andrew Carlsen

    Vice President,
    Head of Investor Relations

    Telephone: +45 3377 9558

    Carl Jakobsens Vej 30
    2500 Valby
    Denmark

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.